Pricing Log in Create free account
Saturday 17 October 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

REGN Healthcare Biotechnology

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS fell 4.68%, free cash flow fell 29.3% and total debt fell 26.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for three consecutive years.

790.74 5.60 −0.70%
Market cap
$82.0B
P/E
18.9×
Fwd P/E
16.5×
Dividend yield
0.47%
F-score
5/9
Altman Z
7.49
Beneish M
−2.53
Dividend safety
77/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Regeneron Pharmaceuticals, Inc. (REGN) P/S ratio

Alert me on P/S ratio

As of 16 October 2026, Regeneron Pharmaceuticals, Inc. (REGN) trades at a P/S ratio of 5.2×. Over the past ten years it has ranged from 3.5× (June 2022) to 18.0× (June 2015); the current reading is higher than 19% of that period. That is below the Biotechnology industry median of 9.7× and above the Healthcare sector median of 3.4×.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2025 5.6× 4.01%
FY2024 5.4× (26.48%)
FY2023 7.4× 16.13%
FY2022 6.3× 52.62%
FY2021 4.2× (32.11%)
FY2020 6.1× (2.16%)
FY2019 6.3× (20.17%)
FY2018 7.8× 13.08%
FY2017 6.9× (15.32%)
FY2016 8.2× (40.01%)

Quarterly newest first

Period P/S ratio Change
Jun 2026 4.1× (23.39%)
Mar 2026 5.4× (4.32%)
Dec 2025 5.6× 37.68%
Sep 2025 4.1× 5.32%
42 more quarters

Against its own ten years

Low 3.5× High 18.0×
Ten-year median 6.7×
Current reading's percentile 21

P/S ratio against peers

Company P/S ratio
REGN Regeneron Pharmaceuticals, Inc. 5.2×
ALNY Alnylam Pharmaceuticals, Inc. compare 6.4×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 6.7×
ARGX argenex SE compare 9.6×
VRTX Vertex Pharmaceuticals Incorporated compare 10.1×
RPRX Royalty Pharma PLC compare 10.8×
MRNA Moderna, Inc. compare 38.9×
RVMD Revolution Medicines, Inc. compare 1,395×
ROIV Roivant Sciences Ltd. compare 3,209×
Biotechnology industry median 9.7×
Healthcare sector median 3.4×
Market median 1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on REGN